JOURNAL DE LINFORMATIONBusiness Directories,Company Directories

Company Name: Corporate Name:	JOURNAL DE LINFORMATION
Company Title:
Company Description:
Keywords to Search:
Company Address:	1107 Rue Ouimet,MONT-TREMBLANT,QC,Canada
ZIP Code: Postal Code:
Telephone Number:	8194258658
Fax Number:	8194257713
Website:
Email:
USA SIC Code(Standard Industrial Classification Code):	271101
USA SIC Description:	Newspapers (Publishers)
Number of Employees:	20 to 49
Sales Amount:	$2.5 to 5 million
Credit History: Credit Report:	Very Good
Contact Person:	Michel Gareau
Remove my name

Company Directories & Business Directories

copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)

Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Previous company profile:
JPDL TREMBLANT INC
JOURNAL TREMBLANT EXPRESS
JOURNAL DE LINFORMATION D

Next company profile:
JOLICOEUR ORNEMENTAL ENR
JOLICOEUR J P ORNEMENTAL ENR
JIM RUSSELL RACING SCHOOL

Company News:

The New England Journal of Medicine | Research Review Articles on . . .
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of
Current Issue | New England Journal of Medicine
Explore the current issue of The New England Journal of Medicine (Vol 393 No 21)
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured exercise program
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
In a phase 3, open-label trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer that recurred or progressed during or after
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP
Medical Management and Revascularization for Asymptomatic Carotid . . .
Improvements in medical therapy, carotid-artery stenting, and carotid endarterectomy call into question the preferred management of asymptomatic carotid stenosis Whether adding revascularization t
Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream . . .
Bloodstream infections are associated with substantial morbidity and mortality Early, appropriate antibiotic therapy is important, but the duration of treatment is uncertain In a multicenter, non
Encorafenib, Cetuximab, and mFOLFOX6 in - The New England Journal of . . .
First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF V600E–mutated metastatic colorectal cancer